*Refresh the page if the below document does not appear.
India-based pharmaceutical company Zydus Lifesciences Ltd. has received exclusive authority for ‘CanAssist Breast’ which is an innovative test which can be used to optimize treatment selection in early-stage (1 & 2) hormone receptor-positive, HER2 receptor negative type of breast cancer cases.
On November 17, 2022, the US regulatory body approved Provention Bio’s “breakthrough” immunotherapy drug named teplizumab (brand name Tzield) for use in patients in stage 2 of Type-1 Diabetes aged 8 years and older.
The securities and Exchange board of India (SEBI) adviced Malaysia’s IHH Healthcare to move forward with its offer to acquire 26.1% market share in Fortis Healthcare company after receiving an order from Delhi high court.
The drugmaker Aurobindo Pharma announced that they have received an EIR (Establishment Inspection Report) from US regulatory body for its API non-antibiotic manufacturing unit at Pydibhimavaram in Andhra Pradesh.
Insurtech company Medi Assist Healthcare Services Limited said that it has acquired a majority stake in UK-based healthcare-related administration service provider Mayfair. Medi Assist will be able to expand its services for customers beyond India and provide global access to medical benefits.
On Wednesday, a panel of health advisors for the US drug health authority recommended the approval of Ardelyx’s new drug (ARDX.O) after more than a year it was rejected. The drug is indicated for chronic kidney disease patients who are on Dialysis.
The CDSCO (Central Drugs Standard Contol
Organization) declared as many as 50 drug
samples out of 1280 samples as NSQ (Not of
Standard Quality) in October 2022. However,
none of the drugs were declared to be
misbranded or spurious.
If you don’t already have an account click the button below to create your account.Create New Account